COMMUNIQUÉS West-GlobeNewswire
-
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
18/06/2026 -
SK pharmteco Announces Strategic Collaboration with Orphan Therapeutics Accelerator for the Development and Manufacturing of Rare Disease Therapies
18/06/2026 -
BiomX Provides Update on Defense Technology Portfolio and Growth Strategy
18/06/2026 -
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026
18/06/2026 -
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)
18/06/2026 -
Legend Senior Living Co-CEO Matt Buchanan Named to Senior Housing News' 2026 Executives to Watch List
18/06/2026 -
Medicana Health Group Conducts Pre-World Cup Health Checks for the Türkiye National Football Team
18/06/2026 -
Derm-Biome’s DB-006 Demonstrates Superior Efficacy in Preclinical Atopic Dermatitis Study: Reduces Itch, Inflammation, and IgE Levels, Outperforms Leading Topical Drugs
18/06/2026 -
PracticeLink Announces Spring 2026 First Practice Fund Scholarship Recipients
18/06/2026 -
Chiesi Global Rare Diseases Highlights Advancements in Lipodystrophy Research at ENDO 2026
18/06/2026 -
NMDP Teams Up with Boozer Brothers to Help More Patients Access Blood Stem Cell Transplants
18/06/2026 -
SK pharmteco annonce une collaboration stratégique avec Orphan Therapeutics Accelerator pour le développement et la fabrication de produits thérapeutiques visant les maladies rares
18/06/2026 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
18/06/2026 -
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
18/06/2026 -
Hi*Ball Energy Arrives in the UK, Leading a New Wave of Clean Energy
18/06/2026 -
Memo Therapeutics AG Presents Complete Phase II Clinical Trial Data for Potravitug in Kidney Transplant Recipients at the American Transplant Congress 2026
18/06/2026 -
Nephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”
18/06/2026 -
Essential Pharma appoints Becki Morison as Chief Executive Officer
18/06/2026 -
Grey Matters Announces Increase to Private Placement Financing to $1.25 Million and Closing of Offering
18/06/2026
Pages